Literature DB >> 19538103

Mechanisms underlying methotrexate-induced pulmonary toxicity.

Youn-Jung Kim1, Mee Song, Jae-Chun Ryu.   

Abstract

BACKGROUND: Methotrexate (MTX) has been widely used for the treatment of inflammatory diseases and rheumatoid arthritis, as well as a variety of tumors. However, MTX-induced pulmonary toxicity is a serious and unpredictable side effect of the therapy, which includes allergic, cytotoxic or immunologic reactions, and is a major clinical problem.
OBJECTIVE: To summarize the mechanisms of action involved in MTX-induced pulmonary toxicity.
METHODS: We reviewed the literature describing MTX-induced adverse pulmonary effects and the mechanisms of action underlying MTX-induced pulmonary toxicity.
CONCLUSION: The mechanisms underlying MTX toxicity are complex. The clinical effects may be attributable to both the anti-inflammatory and immunosuppressive effects of MTX. The mechanisms causing the side effects of MTX include mutation of the genotype, inhibition of transport, MTX-polyglutamates and P-glycoprotein binding with MTX. The p38 MAPK-signaling pathway is especially associated with a pulmonary inflammatory response. These mechanisms can be applied to optimize drug treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19538103     DOI: 10.1517/14740330903066734

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  11 in total

1.  Association of TNFα-308, IFNγ+874, and IL10-1082 gene polymorphisms and the risk of non-small cell lung cancer in the population of the South Indian state of Telangana.

Authors:  Vidyullatha Peddireddy; Siva Prasad Badabagni; Shehnaz Sulthana; Venkata Karunakar Kolla; Sandhya Devi Gundimeda; Hemaprasad Mundluru
Journal:  Int J Clin Oncol       Date:  2016-04-16       Impact factor: 3.402

Review 2.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Authors:  Osamu Matsuno
Journal:  Respir Res       Date:  2012-05-31

3.  Chronic inflammatory diseases are stimulated by current lifestyle: how diet, stress levels and medication prevent our body from recovering.

Authors:  Margarethe M Bosma-den Boer; Marie-Louise van Wetten; Leo Pruimboom
Journal:  Nutr Metab (Lond)       Date:  2012-04-17       Impact factor: 4.169

4.  Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937.

Authors:  Nancy J Olsen; Charles F Spurlock; Thomas M Aune
Journal:  Arthritis Res Ther       Date:  2014-01-20       Impact factor: 5.156

Review 5.  Current Treatment for Myositis.

Authors:  Simone Barsotti; Ingrid E Lundberg
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-09-15

6.  A Case of Methotrexate Neurotoxicity Presented as Status Epilepticus, Encephalopathy, and High Fever.

Authors:  Itay Ayalon; Shirley Friedman; Yoav Binenbaum; Noga Oppenheimer; Shelly Shiran; Galia Grisaru-Soen; Shimrit Uliel-Sibony; Miguel Glatstein; Jennifer Melissa Kaplan; Efraim Sadot
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

7.  Twenty-four-week oral dosing toxicities of Herba Siegesbeckiae in rats.

Authors:  Jia-Ying Wu; Yuen-Cheung Chan; Hui Guo; Ying-Jie Chen; Yu-Xi Liu; Hua Yi; Zhi-Ling Yu
Journal:  BMC Complement Med Ther       Date:  2020-11-11

Review 8.  Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response.

Authors:  Huanhuan Yan; Rui Su; Hongwei Xue; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

9.  Dietary transforming growth factor-beta 2 (TGF-β2) supplementation reduces methotrexate-induced intestinal mucosal injury in a rat.

Authors:  Shani Ben-Lulu; Yulia Pollak; Jorge Mogilner; Jacob Bejar; Arnold G Coran; Igor Sukhotnik
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Efficacy of clarithromycin as a protective agent in the methotrexate-induced pulmonary fibrosis model.

Authors:  Serdar Kalemci; Orhan Akpınar; Yelda Dere; Aydın Sarıhan; Arife Zeybek; Özgür Tanriverdi
Journal:  Kardiochir Torakochirurgia Pol       Date:  2018-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.